| Previous close | 5.47 |
| Open | 5.47 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 195.00 |
| Expiry date | 2025-01-17 |
| Day's range | 5.47 - 5.47 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Financial Times
Reversal of fortunes for Covid-19 vaccine winners
At the height of the pandemic, investors clamoured to buy vaccine makers, the closest thing to a sure bet. Shares in Pfizer, which developed a vaccine and an antiviral drug, have plummeted 46 per cent from their peak in late 2021, while its German vaccine partner BioNTech is down 75 per cent and rival Moderna has plunged 79 per cent. Less successful vaccine makers have fallen back even more significantly: shares in Novavax, whose Covid shot has sold far fewer than the messenger RNA jabs, have fallen 97 per cent since early 2021.
BloombergScientists Behind Pfizer and Moderna mRNA Vaccines Win Nobel
(Bloomberg) -- Two scientists won the Nobel Prize in medicine for research that laid the groundwork for some of the best-selling medicines of all time: the messenger-RNA vaccines against Covid-19.Most Read from BloombergWhy a US Recession Is Still Likely — and Coming SoonAirbnb Is Fundamentally Broken, Its CEO Says. He Plans to Fix It.Severe Crash Is Coming for US Office Properties, Investors SayBond Selloff Batters Stocks, But Spares Big Tech: Markets WrapJPMorgan’s Dimon Predicts 3.5-Day Work
Motley Fool3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
These companies are helping change medicine; they could make boatloads of money along the way.
